MYO5B and neoplasm: In summary, our data demonstrate that LRP5-overexpressing osteocyte-derived CM exerts anti-tumor and bone-protective effects in vivo, and that LIMA1 and MYO5B may be relevant factors contributing to these actions within the bone microenvironment.